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Abstract
Background: The Dead Sea region, the lowest in the world at 410 meters below sea level, is considered a potent
climatotherapy center for the treatment of different chronic diseases.
Objective: To assess the prevalence of chronic diseases and the quality of life of residents of the Dead Sea region
compared with residents of the Ramat Negev region, which has a similar climate, but is situated 600 meters above
sea level.
Methods: An observational study based on a self-administered questionnaire. Data were collected from kibbutz
(communal settlement) members in both regions. Residents of the Dead Sea were the study group and of Ramat
Negev were the control group. We compared demographic characteristics, the prevalence of different chronic
diseases and health-related quality of life (HRQOL) using the SF-36 questionnaire.
Results: There was a higher prevalence of skin nevi and non-inflammatory rheumatic diseases (NIRD) among Dead Sea
residents, but they had significantly higher HRQOL mean scores in general health (68.7 ± 21 vs. 64.4 ± 22, p = 0.023)
and vitality (64.7 ± 17.9 vs. 59.6 ± 17.3, p = 0.001), as well as significantly higher summary scores: physical component
score (80.7 ± 18.2 vs. 78 ± 18.6, p = 0.042), and mental component score (79 ± 16.4 vs. 77.2 ± 15, p = 0.02). These
results did not change after adjusting for social-demographic characteristics, health-related habits, and chronic diseases.
Conclusions: No significant difference between the groups was found in the prevalence of most chronic diseases,
except for higher rates of skin nevi and NIRD among Dead Sea residents. HRQOL was significantly higher among
Dead Sea residents, both healthy or with chronic disease.
Introduction
The Dead Sea (DS) region has a unique climate. Its special
therapeutic climatic advantages are recognized throughout
the world. For many years this geographical area has
served as a climatotherapy center for the treatment of var-
ious skin and rheumatic diseases [1-4], as well as pulmon-
ary, cardiovascular, and gastrointestinal diseases [5-8].
The DS is situated in the Syrian-African Rift Valley.
At 410 meters below sea level it is the lowest place in
the world. Its geographic and meteorological character-
istics generate a rare combination of climatic character-
istics including:
1. The highest barometric pressure on earth (800 mm
hg) with a partial oxygen pressure (PIO2) of 8% more
than at sea level. This has therapeutic advantages in
several respiratory and cardiovascular diseases [9,10].
2. A unique UV radiation, which is typical only of the
DS region. UVB rays with a wavelength between 280-
320 nanometers are differentiated from UVA rays with
a wavelength between 320-400 nanometers. UVB
waves cause the bulk of the skin damage (sun burns).
The amount of radiation from both types of rays is
reduced at the DS since they have to pass through an
additional 420 meters to reach the ground. Further-
more, the high temperatures in the DS region cause
significant evaporation of Dead Sea salts so the region
has a sort of “vapor haze” that blocks radiation. The
extent of blockage depends on the wavelength of the
UV rays so that those with a shorter wavelength, UVB,
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ratio is higher at the DS than anywhere else in Israel
and in the world.
3. A relatively low humidity (below 40%).
4. A paucity of rain (a few mm annually).
5. About 330 days of sunshine each year.
These unique environmental characteristics give the DS
an advantage in the treatment of skin diseases such as
psoriasis [11-13], atopic dermatitis [14], rheumatic dis-
eases such as rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis, fibromyalgia and osteoarthritis
[15-17], pulmonary diseases such as asthma [5] and
COPD [10], and cardiovascular disease [6,18].
Previous studies assessed the climatic effects of the DS
on patients with chronic diseases who came to the region
for a short treatment period. The present study, in con-
trast to previously published studies, was a comparative
study of the prevalence of chronic diseases and quality of
life among DS residents and a control population of indi-
viduals who do not reside in the DS region, but in a
region with a similar hot and dry desert climate, except
for the differences in barometric pressure and UV
radiation.
Materials and methods
Study population
The study population was comprised of kibbutz residents
in the southern desert area of Israel. The kibbutz, a com-
munal settlement based on socialist ideology, is among
the most economically homogeneous societies in the
western world. The study group consisted of residents of
five kibbutzim in the DS region. These kibbutzim were
selected as the main settlements with permanent inhabi-
tants of the region. The control group consisted of resi-
dents of two kibbutzim in the Ramat Negev (RN) region,
which is also in the southern desert, just 100 km from
DS area, and also has a hot and dry desert climate. These
twoKibbutzim were selected in order to have as homoge-
neous a control group as possible. Both regions are spar-
sely populated. In contrast to the DS region, the RN
region is located in the mid-Negev heights. It is the high-
est region in the Negev desert located about 600 meters
above sea level with barometric pressure of 710 mmHg.
The mean annual rainfall in this region is 100 mm com-
pared to few mm at the DS region.
The participants in both groups had similar socioeco-
nomic, cultural, ethnic and occupational backgrounds
[19].
Inclusion criteria were residents of the two regions,
above the age of 18, who agreed to complete the ques-
tionnaire. Individuals who resided in the two regions for
less than a year were excluded from the study.
Study design
Study participants completed a structured self-adminis-
tered questionnaire that was distributed at primary
care clinics and via the kibbutz internal mail system.
Participation was on a voluntary basis. The question-
naire had two parts. The first part assessed baseline
characteristics including socio-demographic variables
such as age, family status, place of work (indoors or
outdoors), life habits (tobacco and/or alcohol), and
chronic diseases. The participants had to indicate the
presence or absence of chronic diseases from a list of
chronic diseases.
The second part was a validated SF-36 questionnaire
of the Medical Outcomes Study (MOS), to assess
health-related quality of life (HRQOL). The SF-36 ques-
tionnaire contains 36 items measuring health across
eight areas or domains: Physical Functioning (PF) 10
items; Social Functioning (SF) 2 items; Role Limitations
due to physical problems (RP) 4 items; Role Limitations
due to emotional problems (RE) 3 items; Mental Health
(MH) 5 items; Vitality (VT) 4 items; Bodily Pain (BP) 2
items and General Health perceptions (GH) 5 items.
There is also an additional item on perceived changes in
health status over the past 12 months. Four scales (PF,
RP, BP and GH) make up the Physical Component
Summary (PCS) measure and the other four scales (VT,
SF, RE and MH) make up the Mental Component Sum-
mary (MCS). Scores are coded for each dimension,
summed and transformed to generate a score from 0
(worst possible health state) to 100 (best possible health
state) [20-22]. The SF-36 has proven useful in surveys of
general and sick populations, comparing the relative
burden of diseases, and in differentiating the health ben-
efits produced by a wide range of different treatments
[23]. The SF-36 Health survey has been translated to
and validated in Hebrew [24].
The study was approved by the Helsinki committee of
Soroka University Medical Center, Beer-Sheva.
Statistical analysis
The baseline characteristics were compared between the
two study groups using the Chi-square and t-tests. Mul-
tivariate analyses, using a logistic regression model, were
conducted to compare the prevalence of the investigated
chronic diseases, adjusted for demographics and health-
related habits. Comparisons of the HRQOL components
was performed with Mann-Whitney U test, and for mul-
tivariate analysis linear regression models were com-
puted [25]. The dependent variables in these models
were the HRQOL scales. The independent variables for
the models were demographics, health-related habits
and chronic conditions. A p-value lower than 0.05 was
considered significant for all statistical analyses.
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Three hundred three of 730 residents from the DS
(45%) region completed the study questionnaire com-
pared to 251 of 710 (35%) from the RN region.
Table 1 summarizes the socio-demographic and
chronic disease data for the two study groups. DS inha-
bitants were younger, with a lower percentage of mar-
ried participants and a higher percentage of participants
who worked outdoors.
The univariate analyses showed no significant differ-
ence in the prevalence of most chronic diseases between
the two groups, except for a significantly higher percen-
tage of skin nevus (p = 0.008) and non-inflammatory
rheumatic diseases (NIRD) (p = 0.028) in the DS group
(Table 2).
Of the 69 DS participants who reported skin disease,
33% were treated with oral drugs and skin creams,
compared to 69% of 29 corresponding participants in
the control group (p = 0.001).
HRQOL scores were significantly higher among DS
residents in the GH (68.7 ± 21 vs. 64.4 ± 22, p = 0.023)
and VT (64.7 ± 17.9 vs. 59.6 ± 17.3, p = 0.001) cate-
gories, and in the summary measures: PCS (80.7 ± 18.2
vs. 78 ± 18.6, p = 0.042), and MCS (79 ± 16.4 vs. 77.2 ±
15, p = 0.02) (Figure 1).
After adjustment for demographics (including age dif-
ferences), health-related habits and chronic diseases, the
difference in HRQOL increased. The DS residents had
higher HRQOL scores in more categories (including
VT, BP, GH, and RP) as well as in the PCS and MCS
summary measures (Table 3).
Discussion
The main purpose of the study was to assess whether
there is a difference in the prevalence and severity of
chronic diseases, as well as HRQOL, between residents
of an area below sea level with a unique elevated baro-
metric pressure and a unique solar spectrum of UV
light, and residents of an area above sea level.
The DS and RN regions are both sparsely populated,
dry desert areas in the southern part of Israel. However,
t h eD Si st h el o w e s tp l a c ei nt h ew o r l da n dh a su n i q u e
geographical and meteorological characteristics that cre-
ate a rare combination of climate conditions that are
considered conducive to health and HRQOL.
The results of previous studies have demonstrated the
advantage of the DS region for climatotherapy. Most of
these studies examined the health benefits of the DS
region for patients with chronic diseases who came to
the DS for treatment. None of these studies assessed
permanent residents of the DS region to determine
whether the affects of this unique climate are beneficial
to residents of the region in terms of the prevalence of
chronic diseases and HRQOL. Thus, for the first time,
the study group consisted DS region residents who were
compared with a control group of individuals who live
in the same desert area of southern Israel, but at a
much higher altitude, aboves e al e v e la n dw i t h o u tt h e
unique climate characteristics of the DS.
Although there were similar ethnic and socioeconomic
characteristics between the study groups, the DS popu-
lation was younger, had fewer married participants, and
was more likely to work outdoors (the last two variables
may be related to the age differences). After adjusting
for these variables (including age difference) we still
found differences between the groups in the prevalence
of NIRD and skin nevus. We cannot determine, on the
basis of the study data, whether this increased preva-
lence reflects an influx of individuals with chronic dis-
eases to the DS region in the belief that it has a
favorable effect on their disease, or that the DS climate
Table 1 Comparison of socio-demographic variables,
health-related habits, and chronic diseases between the
study groups.
Variable DS (n = 303) RN (n = 251) p-value
Age (mean ± SD) 44.7 ± 14.7 53.1 ± 17.5 < 0.001
Gender (% female) 55.6 61.8 0.138
Family status (%)
Single 19.5 11.6 0.002
Married 65.2 73.3
Divorced 12.5 8
Widowed 2.7 6.8
Health-related habits (%)
Works outdoors 35.9 20.3 < 0.001
Smokes 23.3 23.1 0.949
Consumes alcohol 2.7 1.2 0.198
Chronic co-morbidity (%)
Heart disease 5.2 6.8 0.409
Asthma 5.2 4.8 0.839
Other chronic lung disease 4.2 3.6 0.688
Malignancy 7.9 9.2 0.581
Stroke 0.6 2 0.129
Diabetes mellitus 6.4 6.4 0.996
Hypertension 17.6 17.5 0.989
Psychiatric disease 4.2 3.6 0.688
Inflammatory bowel disease 0.6 0.4 0.729
Skin disease
Inflammatory 5.5 4.8 0.005
Skin nevi 15.5 6.8
Rheumatic disorders
Inflammatory 2.1 4 0.15
Non-inflammatory 30.6 24.7
Vascular disease 8.2 12.4 0.097
DS = Dead Sea group.
RN = Ramat Negev group.
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Variable OR (95%CI)
Unadjusted
p-value OR (95%CI)
Adjusted**
p-value
Heart disease 0.75 (0.37;1.50) 0.409 1.65 (0.60;4.49) 0.328
Asthma 1.08 (0.51;2.31) 0.839 0.80 (0.29;2.20) 0.661
Other chronic lung disease 1.19 (0.51;2.80) 0.688 1.31 (0.41;4.18) 0.649
Malignancy 0.85 (0.47;1.52) 0.581 1.24 (0.56;2.72) 0.596
Stroke 0.30 (0.05;1.56) 0.129 0
Diabetes mellitus 1.0 (0.51;1.96) 0.996 1.16 (0.49;2.68) 0.73
Hypertension 1.0 (0.65;1.55) 0.989 2.87 (1.48;5.55) 0.002
Psychiatric disease 1.19 (0.51;2.80) 0.688 2.12 (0.76;5.92) 0.15
Inflammatory bowel disease 1.52 (0.14;16.91) 0.729 0.72 (0.035;14.49) 0.828
Skin disease
Inflammatory 1.15 (0.54;2.43) 0.716 1.09 (0.46;2.58) 0.842
Skin nevi 2.52 (1.42;4.48) 0.001 2.49 (1.27;4.90) 0.008
Rheumatic disorders
Inflammatory 0.55 (0.20;1.39) 0.187 0.88 (0.29;2.71) 0.83
Non-inflammatory 1.34 (0.93;1.95) 0.117 1.69 (1.06;2.69) 0.028
Vascular disease 0.63 (0.37;1.09) 0.097 0.92 (0.46;1.86) 0.824
* For all comparisons, Ramat Negev group used as the reference group.
**Adjusted for socio-demographic variables and health-related habits.
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Figure 1 Comparing SF-36 quality of life scores (Mean and 95% Confidence Interval) between DS inhabitant and control group.P F-
Physical Function (p = 0.387). RE - Role-Emotional (p = 0.560). VT - Vitality (p = 0.001). MH - Mental Health (p = 0.152). SF - Social Function (p =
0.868). BP - Bodily Pain (p = 0.071). GH - General Health (p = 0.023). RP - Role-Physical (p = 0.245). MCS - Mental Component Summary (p =
0.020). PCS - Physical Component Summary (p = 0.042). * Significant difference of scores between Dead See and Control groups (p < 0.05).
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not find any national immigration data or scientific lit-
erature showing a trend for people with chronic disease
to immigrate to known climatotherapy areas, but this is
an issue that should be investigated further.
Another finding was that DS region residents with skin
disease use less oral medication and/or skin cream. This
might be because their skin disease is less severe in this
region because of its beneficial climatotherapeutic effect.
Studies published over the past 40 years [13,14,26,27]
have shown that the DS region has a significant clima-
totherapeutic effect on skin disease (psoriasis, atopic der-
matitis, vitiligo, acne, mycosis fungoides and psoriatic
arthritis), but there have been no previous reports of skin
nevi among the DS residents. Our finding is surprising in
light of the region’s unique UV radiation filtration. The
carcinogenic effect of sun exposure and other environ-
mental factors that can cause pre-malignant or malignant
skin lesions in DS region residents has not been studied.
There have been studies of a late carcinogenic sun expo-
sure risk in patients with skin disease treated for non-
malignant skin conditions by therapeutic exposure to the
sun. The results of these studies are non-conclusive or
controversial [28-30]. A recently published study [31]
showed that sun exposure in the DS was not associated
with an increased risk of skin cancer or melanoma, but
contended that UV radiation exposure at the DS region
m a yp l a yar o l ei nt h ed e v e l o p m e n to fs k i nd a m a g e .
Another study [32] recommended reduction of the
amount of daily therapeutic DS sun exposure to get the
same therapeutic effect with decreased risk of damage.
We cannot determine, on the basis of the present results,
whether the higher prevalence of skin nevi is due to
environmental factors in the DS region or can be attribu-
ted to a tendency of DS region residents to take fewer
protective measures due to a common, but mistaken,
belief that they are protected in this region.
Residents in the DS region, both healthy and with
chronic disease had significantly higher HRQOL
measures than residents in the RN region. The differ-
ence was even stronger after adjustment for socio-
demographic variables and chronic diseases. It is not
clear from the results of the present study whether this
difference is due to the climatotherapeutic characteris-
tics of the DS region, or to other non-biological envir-
onmental characteristics. Previous studies showed that
the DS region has a beneficial therapeutic effect on
patients with chronic diseases who came the DS as
health tourists [33,34]. These studies demonstrated
reduced pain, improved strain and physical task perfor-
mances, improved energy and general health parameters,
and improved emotional and social parameters after the
stay in the DS region.
However, these studies were conducted on patients
who came to the DS region for recreational as well as
therapeutic purposes, which may cause a methodological
bias in terms of improved HRQOL. In the present study
we examined the DS region’s effects on residents who
have lived and worked there for a long time. The results,
which demonstrate higher HRQOL measures for healthy
and chronically ill residents, reinforce the results of pre-
vious studies that the DS region has potent climatother-
apeutic effects.
Potential limitations of this study include its small
sample size. Although more than 40 percent of the
population responded to our questionnaire forms, the
participating kibbutzim had a total population of only
several hundreds residents with relatively few chronically
ill patients. As participation in this study was on a
voluntary basis we cannot be sure that the enrolled indi-
viduals are totally representative of the entire region
population.
In this study we did not assess the clinical severity of
the patients’ chronic diseases. One could argue that the
fact that many HRQOL parameters are better in the DS
region is an indirect marker of less severe and disabling
chronic disease in the region, but we cannot prove this
assumption based on the results of the study.
Table 3 Comparative multivariate analysis of SF-36 quality of life scores between the study groups*
SF-36 scale Regression Coefficient (B) Standard Error of B Standardized Regression Coefficient (Beta) p-value
Physical function (PF) 1.35 1.77 0.04 0.448
Role emotion (RE) 1.8 2.82 0.03 0.524
Vitality (VT) 6.78 1.78 0.19 <0.001
Mental health (MH) 2.59 1.51 0.09 0.088
Social function (SF) 2.64 1.83 0.07 0.151
Bodily pain (BP) 5.75 2.2 0.13 0.009
General health (GH) 4.26 2.13 0.1 0.046
Role physical (RP) 7.4 2.89 0.13 0.011
Mental component summary (MCS) 3.94 1.54 0.13 0.011
Physical component summary (PCS) 4.3 1.66 0.12 0.01
* For all comparisons, Ramat Negev group used as the reference group. Adjusted for socio-demographic variables and health-related habits.
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at below sea level caused the higher prevalence of skin
nevi and NIRD.
We tried to assess changes in disease severity in
chronically ill patients who live in the DS area, but
stayed for a period of time in places above sea level.
However, we were not able to draw any conclusions
because of a very low response rate.
Future prospective studies should assess the clinical
characteristics of different chronic diseases and compare
their course, severity, and clinical outcome between resi-
dents of the DS region and other comparison populations.
We conclude that HRQOL is significantly higher
among both healthy and chronically ill residents of the
DS region compared with residents of the control group
region, although more residents in the region have skin
nevi and NIRD.
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